Download Full Text (628 KB)

Document Type



Over the years, oncologists are better able to fight cancer and have increased cancer survival, but we are also finding that these lifesaving therapies can affect the heart and other parts of the body in a negative way. Chemotherapy is excellent at destroying cancer cells, but it also causes collateral damage to other healthy cells. There are certain chemotherapeutic agents that are known to cause cardiotoxicity. Currently we are monitoring the heart function of the patients who are receiving these cardiotoxic drugs prior to starting the chemotherapy as well as during and after treatment. However, there are currently no recommendations for what can be done to prevent the cardiotoxicity. The intention of this scholarly review is to look into the benefits and compelling results in adrenergic beta antagonists and HMG CoA reductase inhibitors to reduce the risk of cardiotoxicity during chemotherapy in oncology patients. The goal of this paper is to look at the research and hopefully conclude that either beta antagonists or hmg CoA reductase are a reliable option to prevent chemotherapy induced cardiotoxicity. An extensive literature review was performed and at this time, there are no concrete benefits of using either a beta blocker or a statin to reduce chemotherapy induced cardiotoxicity. In the research that has been done, there is some evidence of using these agents to protect the heart. More long term studies need to be conducted as well as more precise inclusion terms need to be used, such as the exact chemotherapy regimen or the particular cardioprotective medication that is used in the study. At this time, recommendations to prevent chemotherapy induced cardiotoxicity remains inconclusive.


Physician Assistant Studies

Date of Work


Publication Date



Cancer, oncologist, beta-antagonist, HMG-CoA reductase inhibitor, Chemotherapy, cardiotoxicity, doxorubicin. Anthracyclines


Medicine and Health Sciences

Use of beta antagonists or HMG CoA reductase inhibitors for cardio protection during chemotherapy in oncology patients